Lilly(Eli) & Co
LLY
Market Cap$780.46B
Close$
Earnings Call Q2 2024
August 8, 2024 - AI Summary
Revenue grew 36% in Q2, driven by strong performance of new products such as Mounjaro and Zepbound.
The company expects momentum to accelerate through the rest of the year, raising its revenue guidance by $3 billion.
Lilly achieved several key pipeline milestones, including FDA approval for Kisunla (donanemab) for Alzheimer's disease and positive Phase 3 results for tirzepatide in heart failure with preserved ejection fraction and obesity.
Exclusive for Stockcircle Pro members
Sign up
$438.34
52.5% downside
Current Fair Value
52.5% downsideOvervalued by 52.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $780.46 Billion |
|---|---|
| Enterprise Value | $809.76 Billion |
| Dividend Yield | $4.8479 (0.59%) |
| Earnings per Share | $6.79 |
| Beta | 0.71 |
| Outstanding Shares | 950,405,386 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 127.14 |
|---|---|
| PEG | 186.23 |
| Price to Sales | 23.09 |
| Price to Book Ratio | 65.98 |
| Enterprise Value to Revenue | 20.8 |
| Enterprise Value to EBIT | 74.32 |
| Enterprise Value to Net Income | 110 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 2.4 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Lilly(Eli) & Co
CEO: David Ricks